Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 55

recruiting
3 987
countries
28
conditions
2 109

761 trials match your criteria

Anaemia+1

Not recruiting

Study of SEL120 Monohydrochloride for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride

Pseudomonas infection

Not recruiting

Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin

Plasma cell myeloma

Not recruiting

Study Comparing Belantamab Mafodotin with Pomalidomide and Dexamethasone to Bortezomib with Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Plasma cell myeloma

Not recruiting

Study of iberdomide alone or with drug combinations for patients with multiple myeloma: testing safety and effectiveness of different doses

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan

Study of enzalutamide alone versus enzalutamide with radium-223 combination in patients with bone metastatic castration-resistant prostate cancer with mild or no symptoms

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib

Neoplasm

Not recruiting

Study on the Effectiveness of Inavolisib, Atezolizumab, and Entrectinib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alectinib

Plasma cell myeloma

Not recruiting

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine

Study on Durvalumab and Tremelimumab for Patients with Advanced Liver Cancer Not Treatable by Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.